source
- Par Health recalls two lots of Brevital Sodium injection over cellulose particlesPar Health announced a voluntary recall of two lots of its Brevital® Sodium 500 mg/vial for injection after detecting particulate matter identified as cellulose. The recall is being executed at th…
- Argenx halts Phase 3 Sjögren's trial as celiac disease data brings mixed resultsArgenx disclosed on Thursday that it is ending its Phase 3 trial in Sjögren's syndrome after the study failed to meet its primary endpoint. The decision came alongside the release of encouraging r…Endpoints · 12d agoNegative readoutNegative